Company intelligence / Profile preview

Cilag Holding

Schaffhausen, Schaffhausen, Switzerland

Ownership: Private
Employees: ~1900
Development stage: Other

Overview

Cilag, as part of Johnson & Johnson, supports the clinical and commercial supply chain for a global product portfolio. Its subsidiary/facility was involved in the acquisition of Covagen (FynomAb platform; lead bi-specific antibody COVA 322 reached Phase Ib for psoriasis). Various advanced-stage drugs (some registered under the Janssen-Cilag umbrella) are commercially available in cancer, immunology, and infectious diseases[2][3][4][8].

Therapeutic areas: OncologyInfectious DiseasesDermatologyGastroenterology
Modalities: Small moleculeMonoclonal antibodyBiologicAutologous CAR-T cell therapyProtein-based therapeutics
Industry: Pharma

Partnerships

Covagen (acquired partner)Internal partnerships within Johnson & Johnson, including Janssen

Beyond the preview

Go deeper on Cilag Holding.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Cilag Holding.

Explore the full profile